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IFN-c signaling, with the synergistic contribution of
TNF-a, mediates cell specific microglial and astroglial
activation in experimental models of Parkinson’s
disease
C Barcia1,2, CM Ros1,2, V Annese1,2, A Go´mez1,2, F Ros-Bernal1,2, D Aguado-Yera1,2, ME Martı´nez-Paga´n1, V de Pablos1,2,
E Fernandez-Villalba1,2 and MT Herrero*,1,2
To through light on the mechanisms underlying the stimulation and persistence of glial cell activation in Parkinsonism, we
investigate the function of IFN-c and TNF-a in experimental models of Parkinson’s disease and analyze their relation with local
glial cell activation. It was found that IFN-c and TNF-a remained higher over the years in the serum and CNS of chronic
Parkinsonian macaques than in untreated animals, accompanied by sustained glial activation (microglia and astroglia) in the
substantia nigra pars compacta. Importantly, Parkinsonian monkeys showed persistent and increasing levels of IFN-cR signaling
in both microglial and astroglial cells. In addition, experiments performed in IFN-c and TNF-a KO mice treated with MPTP
revealed that, even before dopaminergic cell death can be observed, the presence of IFN-c and TNF-a is crucial for microglial and
astroglial activation, and, together, they have an important synergistic role. Both cytokines were necessary for the full level of
activation to be attained in both microglial and astroglial cells. These results demonstrate that IFN-c signaling, together with the
contribution of TNF-a, have a critical and cell-specific role in stimulating and maintaining glial cell activation in Parkinsonism.
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Parkinson’s disease (PD) is characterized by the rapid and
unpredictable loss of dopaminergic neurons located in a small
mesencephalic nucleus, the Substantia Nigra pars compacta
(SNpc), the cause of which remains unknown. Recent
evidence has demonstrated that local inflammation, primarily
mediated by glial cells, may contribute to this neuronal
degeneration. In fact, post-mortem analysis of the SNpc of
PD patients has revealed increased numbers of activated
microglial1 and astroglial cells,2 reflecting persistent inflam-
mation and consequent active nerve degeneration. Likewise,
the post-mortem study of a group of drug addicts accidentally
intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), a neurotoxin that specifically kills dopaminergic
neurons, showed the same maintained glial reaction in the
SNpc many years after the neurotoxin insult.3 Importantly,
experimentally induced Parkinsonian monkeys showed an
identical glial response years after MPTP injection, which was
also confined to the SNpc.4,5 This indicates that the glial
reaction and inflammatory response persist over many years
in Parkinsonian subjects (human and non-human primates)
despite the absence of any apparent new neurotoxic insult
that might induce this state. However, the mechanisms
involved in the perpetuation of this glial activation in the SNpc
remain unclear.
Pro-inflammatory cytokines are clear candidates to be
implicated in the initiation and self perpetuation of glial
activation in the brain.6,7 Some of these pro-inflammatory
cytokines8–10 show increased levels in the blood serum of
patients with PD and post-mortem analysis of PD patients’
brains show a concomitant increase of these cytokines in the
nigrostriatal system.10 However, the function of this cytokine-
mediated inflammatory reaction observed in the brain, and
also outside the central nervous system (CNS), is poorly
understood, as is the way in which normal resting glia become
activated. It is known that some cytokines, like interferon-g
(IFN-g) and tumor necrosis factor-a (TNF-a), may be involved
in dopaminergic degeneration, and the absence of either
protects dopaminergic neurons in experimental models of PD
in mice.8,11,12 In the present work, we show how IFN-g and
TNF-a are critically involved in the triggering and perpetuation
of glial activation in vivo, in two animal models of PD. In the
first model of chronic Parkinsonian monkeys, we investigate
the putative role of IFN-g and TNF-a in a sustained glial
inflammatory response in the SNpc. We demonstrate that
Received 21.9.10; revised 24.1.11; accepted 17.2.11; Edited by D Bano
1Clinical and Experimental Neuroscience, University of Murcia, Campus de Espinardo, 30071 Murcia, Spain and 2Centro de Investigacio´n Biome´dica en Red sobre
Enfermedades Neurodegenerativas (CIBERNED), School of Medicine, University of Murcia, Campus de Espinardo, 30071 Murcia, Spain
*Corresponding author: MT Herrero, Clinical and Experimental Neuroscience (NiCE-CIBERNED), CIBERNED, School of Medicine, University of Murcia, Campus de
Espinardo, 30100 Murcia, Spain. Tel: þ 34 868 88 46 83; Fax: þ 34 868 88 41 50; E-mail: mtherrer@um.es
Keywords: Parkinson’s disease; inflammation; glial cells; pro-inflammatory cytokines; IFN-g; TNF-a
Abbreviations: PD, Parkinson’s disease; SNpc, Substantia Nigra pars compacta; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; CNS, central nervous system;
IFN-g, interferon-g; TNF-a, tumor necrosis factor-a; HLA-DR, human leukocyte antigen DR; GFAP, glial fibrilary acidic protein; IFN-gR, IFN-g receptor; STAT1, signal
transducers activators of transcription type 1; pSTAT1, phosphorylated signal transducers activators of transcription type 1; Iba-1, ionized calcium binding adapter
molecule 1
Citation: Cell Death and Disease (2011) 2, e142; doi:10.1038/cddis.2011.17
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
www.nature.com/cddis
IFN-g signaling, with the contribution of TNF-a, may have a
crucial role in stimulating the persistent activation of both
microglia and astrocytes in a cell-specific manner. The
amount of glial IFN-g increased in the SNpc of Parkinsonian
monkeys and was strongly correlated with dopaminergic
neuronal degeneration. Importantly, STAT1, a crucial tran-
scription factor activated in response to IFN-g, remains
phosphorylated locally in glial cells of the SNpc of Parkinso-
nian monkeys years after MPTP exposure. However, while
TNF-a also remained high in MPTP-treated monkeys, it did
not correlate so strongly with the dopaminergic loss. In the
second model, using KO mice lacking IFN-g or TNF-a, we
investigated the particular role of IFN-g and TNF-a in glial
activation before dopaminergic neuronal loss could occur
and observe that both cytokines are responsible for enhancing
the activation of the surrounding glial cells in a reciprocal
manner. These results throw light on which cytokines are
specifically involved in the glial-mediated inflammatory
response in Parkinsonism and suggest two specific
therapeutic targets (IFN-g and TNF-a) to diminish local
inflammation in PD.
Results
Increase of IFN-c and TNF-a in blood serum of
Parkinsonian monkeys. Serum samples from 20 young
MPTP-treated adult macaques were analyzed to elucidate
which pro-inflammatory cytokines may be involved in chronic
Parkinsonism. Susceptible MPTP-treated monkeys
(Parkinsonian) showed Parkinsonian symptoms, displaying
sporadic freezing phenomena and different degrees of
bradykinesia and akinesia, while some presented action
tremor, paradoxical kinesia and, occasionally, vertical and
horizontal saccadic ocular movements. However, some
monkeys did not show Parkinsonian symptoms
(asymtomatic) despite the numerous MPTP injections
(Table 1). Susceptible monkeys also displayed a typical
Parkinsonian posture (Figures 1a and b) in contrast to the
asymptomatic animals that showed postures similar to
controls. Before the postmortem analysis were conducted,
several characteristic pro-inflammatory cytokines, IFN-g,
TNF-a, IL-16, IL-6, IL-8 and TNF-b, were measured in
blood serum samples of the MPTP-treated monkeys.
Importantly, we observed a sustained increase of IFN-g
and TNF-a, (Figures 1c and d) in contrast with other pro-
inflammatory cytokines (Supplementary Figure 1) as
demonstrated by ELISA measurements. Note that IL-1b
was not included in this study because no changes were
observed in this cytokine in a previous analysis performed in
chronic Parkinsonian monkeys.13
Before proceeding with a deeper analysis of these two
cytokines in the CNS, we analyzed the level of dopaminergic
degeneration and gial activation in the MPTP-treated mon-
keys. When dopaminergic neuronal loss was analyzed in the
SNpc of MPTP-treated monkeys, only monkeys with evident
Parkinsonian symptoms presented a high degree of dopami-
nergic neuronal loss (Supplementary Figure 2a). However,
asymptomatic monkeys showed a certain, non-significant loss
with respect to control animals (Supplementary Figure 2a).
Parkinsonian animals showed increased levels of both
microglial and astroglial activation, as demonstrated, by the
expression of HLA-DR and GFAP markers, respectively, and
Table 1 Values of the motor score reached by the monkeys, accumulative dose
of MPTP (mg/kg) of each animal and the time of killing after the last MPTP dose
Monkey Sex Motor Score
MPTP
Accumulative
dose mg/kg
Years after
last MPTP
dose
C1 Male 0.0 0 —
C2 Male 0.0 0 —
C3 Female 0.0 0 —
C4 Male 0.0 0 —
C5 Male 0.0 0 —
C6 Male 0.0 0 —
A1 Male 0.0 1.8 1
A2 Male 0.0 1.8 1
A3 Male 0.0 2.1 1
A4 Male 0.0 1.8 1
A5 Male 0.0 1.8 1
A6 Female 0.0 0.9 1
P1 Male 3.5 1.8 1
P2 Female 4.2 0.9 2
P3 Male 5.0 1.8 1
P4 Female 9.2 0.9 2
P5 Male 10.0 3.9 1
P6 Male 10.0 4.2 5
P7 Male 15.0 3.6 5
P8 Male 17.0 2.1 1
Abbreviations: A, asymptomatic animals; C, control animals; P, Parkinsonian animals
Figure 1 Persistent increase of IFN-g and TNF-a in chronic Parkinsonian
monkeys. (a–d) Artist’s sketch (a) of the typical gait posture of a normal monkey
(control) compared with the characteristic Parkinsonian posture (Parkinsonian).
Parkinsonian monkey posture is characterized by curvature of the trunk and rigidity
of the limbs, together with rigidity of the tail (drawings by C.B). (b) Graphs of the
motor score impairment reached by the MPTP-treated monkeys included in the
study. Some animals, despite MPTP administration, did not show symptoms
(asymptomatic). (c) Levels of IFN-g measured by ELISA in serum increase in
Parkinsonian monkeys. (d) Levels of TNF-a measured by ELISA in serum are
increased in Parkinsonian monkeys. *Po0.05 respect to non-Parkinsonian
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by phenotypical changes in both cell types (Supplementary
Figures 2b, 2c and 3). The group of animals killed 5 years after
the last MPTP dose showed slightly higher glial activation,
although the number of animals in this group (5 years) was too
small (n¼ 2) for any statistical differences to be established.
Moreover, the animals from this group had higher motor
scores and suffered greater dopaminergic neuronal loss,
which may bias any observations. Previous studies have
shown that glial activation maintains similar levels despite
acute or chronic protocols of MPTP administration.14
Taken together, these results confirm that in our model of
Parkinsonian macaques, glial cells remain activated over a
number of years. However, since it was thought that pro-
inflammatory cytokines may be involved in glial cell activation,
we proceeded to analyze IFN-g and TNF-a levels in the CNS of
the Parkinsonian monkeys.
Increase of IFN-c in the CNS of Parkinsonian monkeys.
Sections of the SNpc were stained with antibodies against
IFN-g and western blot analysis was performed in
homogenates of the SNpc to test the specificity of the
antibodies and to quantify the amount of IFN-g. Few IFN-gþ
cells were seen in the control animals, whereas, MPTP-
treated animals showed a dramatic increase in IFN-gþ cells
in the SNpc (Figures 2a and b). Furthermore, this increase
was more pronounced in animals with evident clinical
symptoms. Western blot analysis demonstrated the
specificity of the IFN-g antibody, and pointed to a similar
increase of IFN-g in the SNpc of Parkinsonian monkeys
(Figure 2c). Importantly, the amount of IFN-g was
closely correlated with motor impairment and dopaminergic
cell death (Table 2). There was also a correlation with
microglial activation, especially as regards phenotypical
changes, but a weak correlation with astroglial activation
(Table 2).
To identify the IFN-g-expressing cell type, adjacent sections
were stained with an antibody against IFN-g combined with
antibodies against Iba-1 or GFAP. Surprisingly, IFN-g
immunoreactivity was primarily observed in the microglia
(Iba-1þ cells), but was absent in the astroglia (GFAPþ cells)
(Figure 2d), which suggests that microglial cells may produce/
release or accumulate IFN-g in the SNpc of Parkinsonian
monkeys. Interestingly, when the IFN-g-expressing microglial
cells were analyzed by detailed confocal microscopy, some
microglial cells showed peri-nuclear IFN-g staining (Figure
2e1), while other cells, with an activated morphology
(increased cell body size and a higher number of ramifica-
tions), expressed IFN-g throughout the entire cytoplasm (cell
body and ramifications) (Figure 2e2). In addition, this increase
in IFN-g-expressing cells corresponded to a higher percen-
tage of microglial cells that express IFN-g in chronic
Parkinsonism (Figure 2f).
Evidence of IFN-cR signaling by glial cells in the SNpc of
chronic Parkinsonian monkeys. Given the increased
expression of IFN-g in the SNpc of chronic Parkinsonian
monkeys, the expression of IFN-g receptor (IFN-gR) was
studied in monkey brain sections to ascertain which cell
types were affected by IFN-g signaling. It was observed that
both microglial cells and astroglial cells are able to express
IFN-gR, as demonstrated by multiple immuno-fluorescence
(Figure 3). Most importantly, as the phosphorylation of
STAT1 is essential for responsiveness to IFN-g, through
stimulation of the IFN-gR, we analyzed the expression of
phosphorylated STAT1 (pSTAT1) in the SNpc of chronic
Parkinsonian monkeys, finding that the number of pSTAT1-
expressing cells was greatly increased in Parkinsonian
animals compared with the control (Figures 4a and b).
Furthermore, we also observed that the increase of pSTAT1
expression was specific for the SNpc and was not observed
in other uninvolved brain regions (Supplementary Figure 4).
In addition, the expression of pSTAT1 was seen in both
microglial and astroglial cells (Figures 4c and d), which
demonstrates that IFN-g signaling may be involved in the
sustained glial activation of both cell types in the SNpc.
TNF-a increases in the CNS of Parkinsonian monkeys.
As stated above, we observed a sustained increase of TNF-a
in chronic Parkinsonian monkeys, as demonstrated by ELISA
measurements in serum. Immunohistochemistry in brain
sections using an antibody against TNF-a revealed a
pronounced increase of TNF-aþ cells in the SNpc of
Parkinsonian monkeys. (Figures 5a and b). Western blot
analysis of homogenates of the SNpc corroborated the
specificity of the antibody and revealed that MPTP-treated
animals presented high levels of TNF-a, the degree of which
was correlated with their Parkinsonian symptoms and with
the level of neuronal degeneration (Figure 5c and Table 2).
However, poor correlation was seen between glial activation
and the amount of TNF-a measured by western blot (Table 2)
probably because of the similar levels shown by
asymptomatic and Parkinsonian monkeys. To identify the
cell type-expressing TNF-a, adjacent sections of the SNpc
were also stained with the antibody against TNF-a combined
with antibodies against Iba-1 or GFAP. Confocal images
demonstrated that TNF-aþ immunoreactivity was primarily
observed in astrocytes, but was very faint or absent in
microglia (Figures 5d and e). Moreover, this increase in
TNF-a-expressing cells corresponded to a higher
percentage of astrocytes that express TNF-a several
years after MPTP insult than observed in intact animals
(Figure 4f).
IFN-c is crucial for microglial activation and TNF-a exerts
a synergistic effect. On the basis of the observations
described above and the fact that IFN-g is highly expressed
in microglia and TNF-a is highly expressed in astroglia in the
SNpc of chronic Parkinsonian monkeys, we used a model of
glial activation in KO mice lacking IFN-g or TNF-a to ascertain
whether the absence of one of these cytokines may have a
differential impact on glial activation. Taking advantage of the
fact that MPTP exerts a rapid glial activation in mice within
24 h (Supplementary Figure 5), KO mice were injected with a
single dose of MPTP (20 mg/kg) and killed before
dopaminergic neuronal loss could be observed (24 h after
MPTP). IFN-g(/), TNF-a(/) and wild-type mice of the
same age and background (C57BL6) were injected with
MPTP and killed 24 h later. Microglial and astroglial activation
were analyzed with confocal microscopy, bearing in mind the
criteria described in the Material and Methods section
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(Supplementary Figure 6). Before dopaminergic loss could
be observed (Figure 6a), wild-type mice (C57BL-6) showed a
specific activation of microglial cells in the SNpc,
characterized by an increase in F4/80 expression
(Figure 6b), a pronounced increase in cell body size
(Figures 6c and d) and also by an increased number of
primary and secondary branches and terminal tips
(Figure 6e).
Importantly, in mice lacking IFN-g (IFN-g(/)), microglial
activation was severely affected. First of all, no changes in the
Figure 2 Increase of IFN-g in the SNpc of Parkinsonian monkeys. (a–f): Increase of IFN-gþ cells in brain sections of the SNpc of Parkinsonian monkeys. (a) Confocal
images of immunofluorescence against IFN-g revealed a higher number of IFN-gþ cells in MPTP-treated animals. Scale bar: 100mm. (b) The density of cells was estimated
by stereological criteria and a significant increase in IFN-gþ cells was observed in MPTP-treated animals. (c) Western blot of IFN-g from monkey brain samples. Tissue of the
SNpc from seven different monkeys (1–7) is shown. The Parkinsonian motor score of the monkeys is indicated between brackets. GAPDH was used as house-keeping protein.
The analysis of the optical density of all the studied monkeys, normalized with GAPDH, is represented in Table 2. (d) Multiple fluorescence labeling revealed that IFN-g (red)
co-localize with microglial marker Iba-1 (green) (1). However, astrocyte marker GFAP (green) did not co-localize with IFN-g-expressing cells (red) (2). DAPI staining was used
to mark the cell nuclei (Blue). Scale bar: 50 mm. (e) Higher magnification of two representative IFN-gþ microglial cells. Some of the microglial cells with resting phenotype (1)
presented IFN-g staining mainly confined to the cytoplasm (red) surrounding the cell nucleus (Blue). Other microglial cells with activated phenotype (2) presented IFN-g
staining through the whole cytoplasm. (f) Percentage of IFN-g-expressing microglia (black pie portion (Iba-1þ /IFN-gþ cells)) over the rest of the microglial population (gray pie
portion (Iba-1þ /IFN-g cells)) in the three group of animals. *Po0.05 (one-way ANOVA and Tukey’s test)
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number of F4/80þ cells was observed and, second, the size of
the microglial cells did not increase after MPTP treatment
(Figures 6b-e and Table 3). However, the number of branches
did increase in IFN-g KO mice, which suggests that this
phenotypical change in the microglia is not dependent on
this cytokine. On the other hand, in mice lacking TNF-a (TNF-
a(/)), the microglial cells were slightly activated, as seen
from a slight increase in numbers (F4/80þ cells) and size and
also an increased number of branches and tips (Figures 6b-e
and Table 3), suggesting that TNF-a has a synergistic co-
adjuvant role in activating microglia.
IFN-c signaling with TNF-a contribution is necessary for
astroglial activation. Concomitantly, we observed that
wild-type mice (C57BL-6) show a specific activation of
astroglial cells in the SNpc, characterized by an increased
number of GFAPþ cells (Figures 6b and c), a larger cell body
size (Figures 6c and d) and also by an increased number
of secondary branches and terminal tips (Figures 6c–e).
Importantly, the absence of IFN-g or TNF-a prevented any
increase in the number of astrocytes (GFAPþ cells) in the
SNpc after MPTP treatment (Figure 6b). On the other hand,
reactive GFAP cells showed the characteristic size change
after MPTP treatment and a slight increase in the number of
secondary branches and tips in IFN-g KO animals, which
suggests that IFN-g is not necessary for these morphological
changes (Figures 6b–e). However, the area occupied by
GFAPþ cells and the number of branches and terminal tips
did not change in mice lacking TNF-a (TNF-a(/)),
demonstrating that TNF-a is crucial for the characteristic
phenotypical changes of astrocytes after MPTP intoxication
(Figures 6d and e).
Discussion
In the present work, we show that the persistent release of
IFN-g and TNF-a, among other pro-inflammatory cytokines, is
a crucial factor for perpetuating glial activation in Parkinsonism
(Figures 1, 2, 5, 6 and Supplementary Figure 1) and
importantly, may contribute to neuronal degeneration. This
is important, as it narrows down to two the putative specific
targets to be hit to diminish the glial-mediated inflammatory
Table 2 Pearson’s correlation between the amount of cytokines (IFN-g or TNF-a) measured in the SNpc of monkeys by western blot and (1) the motor impairment,
(2) dopaminergic cell death and (3) activation of microglia or astroglia, measured by the number of activated cells (HLA-DR for microglia and GFAP for astroglia) or the
change of glial phenotype
Microglial activation Astroglial activation
Motor impairment Dopaminergic cell death Number HLA-DR Phenotype Number of GFAP Phenotype
IFN-g 0.91** 0.99*** 0.81+ 0.95*** 0.51 ns 0.89*
TNF-a 0.68+ 0.63+ 0.55 ns 0.47 ns 0.38 ns 0.57 ns
Values of significance for Pearson’s correlation: nsP¼0.1 (non-significant), +Pr0.05, *Po0.02, **Po0.01, ***Po0.001
Figure 3 Microglial and astroglial cells express IFN-gR in the SNpc of MPTP-treated monkeys. (a and b) Sections of the SNpc of MPTP-treated monkeys were immuno-
stained for IFN-gR (Green), combined with either astrocyte marker GFAP (Red in a) or microglial marker Iba-1 (Red in b) and counterstained with DAPI (Blue). Scale bars: in a,
50mm; in b, 40mm
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response in Parkinsonism. By doing so, reducing specifically
the exacerbated glial reaction in the SNpc, DA neurons may
be beneficed and protected. Our results show that such glial
activation is specifically mediated by IFN-g signaling, aided by
TNF-a, and suggest that both cytokines are responsible for
enhancing the activation of the surrounding glial cells in a
reciprocal manner and that a degree of intercellular crosstalk
through both pro-inflammatory cytokines is needed to achieve
full activation of both cell types.
As we demonstrated with KO mice experiments, the
selective absence of IFN-g or TNF-a inhibits the activation of
microglial and astroglial cells in different ways. Importantly,
the absence of INF-g alters the activation of both glial cells,
especially the microglia, after MPTP treatment, which
demonstrates that IFN-g signaling is a crucial cytokine for
such activation in Parkinsonism (Figure 6). Furthermore, the
amount of IFN-g protein in the CNS correlates with glial
activation in chronic MPTP monkeys, but especially with the
Figure 4 Persistent phosphorylation of STAT1 (pSTAT1) in the SNpc of chronic Parkinsonian monkeys. (a–e) Panel (a) shows confocal images of pSTAT1 in a
representative image of the SNpc of a control monkey, asymptomatic and Parkinsonian monkey. DAPI staining is combined to observe the cell nuclei (Blue). High levels of
pSTAT1 staining (Red) can be seen in Parkinsonian monkeys. Scale bar: 100mm. (b) Quantification of pSTAT1þ cells in the SNpc of control, asymptomatic and Parkinsonian
monkeys. A strongly significant increase can be observed in Parkinsonian monkeys. **Po0.01 (one-way ANOVA and Tukey’s test). (c) The pSTAT1 immunostaining in the
SNpc identified astroglia-like cells (1) and microglia-like cells (2). Scale bar: 30 mm. (d) The pSTAT1 immunostaining (Red) was combined with GFAP or Iba-1 antibodies
(Green) and both astrocytes (GFAP) and microglia (Iba-1) were seen to co-localize with pSTAT1. Nuclei were stained with DAPI (Blue). Scale bar: 20 mm. (e) Illustration of the
IFN-g signaling, characterized by the phosphorylation of STAT1, through the activation of IFN-g receptor (IFN-gR) in a microglial cell and an astrocyte
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phenotypical changes in microglia (Table 2). This activation
may be induced and perpetuated by initiation of the STAT1
pathway through stimulation of the IFN-gR present in
microglial and astroglial cells15,16 (Figure 3). This is consistent
with the evidence of STAT1 phosphorylation observed in
astrocytes and microglial cells in the SNpc of Parkinsonian
monkeys (Figure 4) and is concordant with previous results
reported in other inflammatory scenarios in the CNS .
On the other hand, besides the action of IFN-g, the
contribution of TNF-a also seems to be important for glial
activation in Parkinsonism, especially for astrocytes. This is
consistent with the fact that astrocytes are able to release
TNF-a and, at the same time, can also be stimulated by TNF-a
in vitro.17,18 This activation may be particularly related with the
morphology of astrocytes, because the lack of TNF-a results
in the absence of phenotypical changes after MPTP insult in
Figure 5 Persistent increase of TNF-a in the CNS of chronic Parkinsonian monkeys. (a–f) Increase of TNF-aþ cells in the SNpc of Parkinsonian monkeys. (a) Confocal
images of immunofluorescence against TNF-a revealed higher levels in Parkinsonian animals. Scale bar: 100mm. (b) The density of cells was estimated by stereological
criteria and a significant increase of TNF-aþ cells were observed in Parkinsonian animals. (c) Western blot of TNF-a from monkey brain samples. Tissue of the SNpc from
seven different monkeys (1–7) is shown. The Parkinsonian motor score of the monkeys is indicated between brackets. GAPDH was used as house-keeping protein. TNF-a
was specifically detected in the expected band in the SNpc of MPTP-treated monkeys. The quantification of the optical density of all the analyzed monkeys, normalized with
GAPDH, is represented in Table 2. (d) Multiple fluorescence labeling revealed that TNF-a (red) did not co-localize with microglial marker Iba-1 (green) (1). However, astrocyte
marker GFAP (green) co-localized with TNF-a-expressing cells (red) (2). DAPI staining was used to mark the cell nuclei (Blue). Scale bar: 25mm. (e) Higher magnification of a
representative TNF-aþ astrocyte. (f) Percentage of TNF-a-expressing astrocytes (black pie portion (GFAPþ /TNF-aþ cells)) over the rest of the astroglial population (gray
pie portion (GFAPþ /TNF-a cells)) in the three group of animals. *Po0.05 (one-way ANOVA and Tukey’s test)
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Figure 6 IFN-g and TNF-a have a cell specific function in microglial and astroglial activation. (a–f) Activation of the microglia depends on IFN-g and activation of the
astrocytes depends on TNF-a. (a) Quantification of THþ neurons in the SNpc revealed no significant reduction of dopaminergic neurons in any of the experimental groups
24 h after MPTP. (b) Quantification of the number of F4/80þ microglial cells and GFAPþ astroglial cells. In the absence of IFN-g, no increase in the number of F4/80þ or
GFAPþ cells was observed after MPTP treatment. In the absence of TNF-a, a slight increase of F4/80þ cells was observed, but no changes were noted in the number of
GFAPþ cells. *Po0.05 (one-way ANOVA and Tukey’s test). (c) Confocal pictures of microglial cells (Iba-1) and astroglial cells (GFAP) in the SNpc of wild type mice
(C57 BL6), IFN-g KO mice (IFNg(/)) and TNF-a KO mice (TNF-a(/)). Scale bar: 30mm. (d) Quantification of the area occupied by Iba-1 demonstrates that the size of
microglial cells (Iba-1) increases significantly after MPTP treatment. However, in the absence of IFN-g, the microglial cells do not change their size. In TNF-a(/) mice,
microglial cells also increase their size, but to a lesser extent. Quantification of the area occupied by GFAP demonstrated that the size of astroglial cells increases after MPTP
treatment. In the absence of IFN-g, astroglial cells also increase their size after MPTP; however, in the absence of TNF-a, astroglial cells remain unchanged after MPTP.
*Po0.01 with respect to control saline values, wPo0.01 with respect to wild type C57 MPTP (one-way ANOVA and Tukey’s test). (e) Quantification of primary branches
(1ary), secondary branches (2ary) and terminal tips (T) in microglial (Iba-1) and astroglial cells (GFAP). Both microglial and astroglial cells change their phenotype 24 h after
MPTP treatment in wild-type animals (C57BL6). In animals without IFN-g (IFNg(/)), microglial cells show no changes in primary branches, but increased numbers of
secondary branches and terminal tips. In TNF-a KO animals (TNFa(/)), microglial cells show increased numbers of primary, secondary branches and T. However,
astroglial cells remain unchanged in TNF-a(/) mice 24 h after MPTP. *Po0.01, .Po0.05 (one-way ANOVA and Dunnett’s test)
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mice (Figure 6). It seems that TNF-a acts in a synergistic way,
probably enhancing glial activation by the stimulation of the
TNF-aR present in astroglial cells,19 which suggests that
astrocyte activation may be also relevant for the activation of
surrounding astrocytes.
TNF-a and IFN-g showed high levels over several years
following MPTP treatment in our monkeys (Figures 2 and 5) as
occurs in PD patients,8–10,20 which may have contributed to
the long-term glial activation observed and consequently to
dopaminergic loss. Importantly, the amounts of both, IFN-g
and TNF-a in the SNpc correlate with the degree of
neurodegeneration and motor impairment (Table 2). In line
with this, previous reports showed that centrally and systemi-
cally circulating cytokines may exacerbate neurodegenera-
tion in Parkinsonian rats, suggesting that the expression of
cytokines in the CNS and also in the blood stream may be
crucial for full glial activation and dopaminergic degenera-
tion.21
Unlike in primates, mice do not show such persistently
increased cytokine levels in the blood 24 h after MPTP insult
(Supplementary Figure 5), which may be consistent with
transient glial activation.22–24 In fact, previous reports have
shown that MPTP-treated mice merely show a transitory
increase in pro-inflammatory cytokines from 24 h to 72 h after
MPTP insult, which may explain why only some pools of our
mice showed increased levels of IFN-g and TNF-a after MPTP
(Supplementary Figure 5).22–25 Furthermore, the perceptible,
but transient increase in cytokine levels in mice after MPTP is
also dependent on the MPTP treatment regime, and may only
be observed in protocols involving chronic administration.23
Our results also suggest that glial cells may be one of the
main cells responsible for IFN-g and TNF-a release in the
CNS. We first demonstrated that IFN-g is highly increased in
the SNpc, as demonstrated by immunohistochemistry and
western blot analysis. Surprisingly, microglial cells and not
astrocytes showed a high degree of IFN-g expression in the
SNpc of monkeys (Figure 2). The possibility of a role for cells
of myeloid origin, such as macrophages/microglia, as an
additional source of IFN-g is controversial and has received
little attention (for review on this matter see ref. 26). In depth
studies have shown strong evidence that macrophages/
microglia are able to synthesize IFN-g mRNA and produce
IFN-g protein in both resting and activated states.27,28 After
activation, macrophages/microglia show higher levels of
IFN-g and its release may have a crucial role in the activation
of neighboring cells and conduct the local inflammatory
response.26–28 Importantly, the detection and imaging of
IFN-g protein in resting or activated macrophages has been
elusive, and confocal immunofluorescence is the preferable
technique for its cell-associated detection (see review ref. 26,
pg. 288, 2nd paragraph).
Interestingly, the expression of IFN-g can be observed in
both microglial cells with or without an activated phenotype
(Figure 2e). IFN-gþ microglial cells with resting phenotype
show peri-nuclear staining of IFN-g (Figure 2e1). However,
IFN-gþ microglial cells with activated phenotype show a high
content of IFN-g in the cytoplasm, suggesting that highly
activated microglia may be able to produce, release or
accumulate large amounts of IFN-g (Figure 2e2). Control
animals showed a small percentage of IFN-g-expressing
microglia, which significantly increased in MPTP-treated
monkeys (Figure 2f).
In contrast, TNF-a is highly expressed in astrocytes, but not
in microglia in the SNpc of monkeys (Figure 5). TNF-a
immuno-reactivity is observed very close to GFAP expression
in reactive astrocytes (Figure 5e), which suggests that TNF-a
synthesis and/or release may be intimately linked with the
astrocyte cytoskeleton. TNF-a-expressing astrocytes could
also be seen in control animals, but their expression and
percentage increased in Parkinsonian monkeys (Figure 5f).
Recent experiments performed in vitro have concluded that
microglial cells are the initial responders to inflammation and
suggest that astrocytes may amplify the production of
neurotoxic factors after microglial activation.29 These findings
are consistent with the idea that the release of IFN-g by
microglial cells is important for the initiation and maintenance
of microglial and astroglial activation in combination with
TNF-a. Importantly, increasing evidence points to the TNF-a
released by astrocytes as having a deleterious impact on
dopaminergic neurons, as previously described in vitro,30
stimulating the TNF-aR present in the neuron membrane.31
Our results in chronic Parkinsonian monkeys, however,
revealed that IFN-g correlates more strongly with dopaminer-
gic loss than TNF-a, suggesting a prominent role for IFN-g in
cell death.
We conclude that IFN-g and TNF-a are clearly crucial
players in microglial and astroglial activation in Parkinsonism
and may be critical factors in the local perpetuation of glial
activation in the SNpc, contributing to dopaminergic neuronal
degeneration and motor impairment. This strongly suggests
that targeting both cytokines may be a suitable therapy for
reducing this glial-mediated inflammation in PD.
From a clinical point of view, an abundance of data show
that anti-inflammatory treatment may be beneficial for
Table 3 Summary of the results obtained from the analysis of microglia and astroglial activation in the SNpc after MPTP treatment of wild type (C57BL6), IFNg(/)
and TNFa(/) mice
Microglia Increase of F4/80+ cells Increase in # of branches and tips Increase of cell body size
C57BL6 +++ +++ +++
IFNg(/)  ++ 
TNFa(/) + +++ ++
Astroglia Increase of GFAP+ cells Increase in # of branches and tips Increase of cell body size
C57BL6 +++ +++ +++
IFNg(/)  +++ +++
TNFa(/)   
Cell-specific cross-talk between microglia and astroglia in Parkinsonism
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Parkinsonian patients.32 Neuropathological examinations
suggest that persistent glial activation in humans may be
responsible of exacerbating the inflammatory environment
and contribute to neuronal degeneration.1,3 Some anti-
inflammatory drugs have been reported as having an impact
on the development of the disease32 and, interestingly, a
polymorphism, precisely in the HLA-DR gene, has recently
been described as a putative gene that may affect the
susceptibility to PD.33 It is therefore important to tackle the
exacerbated glial response, but only targeting the precise
mechanisms. In particular, the development of specific
antibodies that avert cytokine activity represents a promising
therapy for many CNS disorders.34 We propose that the
manipulation of both these pro-inflammatory cytokines, IFN-g
and TNF-a, which seem to contribute to dopaminergic
neuronal degeneration, could well be relevant for PD therapy
in the near future.
Materials and Methods
Parkinsonian monkeys. The present study uses blood samples and brain
tissue from a colony of chronic Parkinsonian macaques (Macaca fascicularis), which
have been studied for several years in our Primate Unit. All studies were carried out
in accordance with the Guidelines of the European Convention for the protection of
vertebrate animals used for experimental and other scientific purposes of the
Council of Europe of 2006, the Helsinki Declaration, the International Primatological
Society Guidelines and the Guide for the Care and Use of Laboratory Animals (NIH
Guide, revised 1996). Samples obtained from 20 young adult animals of both sexes
were analyzed. A total of 14 animals at 4 years of age were treated with low weekly
intravenous doses of MPTP (0.3 mg/kg) according to previous protocols.35 As each
individual has a very different susceptibility to MPTP, the number of injections varied
depending on the systemic response to the toxin and the motor score reached. The
treatment with MPTP was stopped when: (1) a stable Parkinsonism was achieved,
or (2) when the individual displayed a systemic response that was considered
potentially lethal or (3) when new injections do not affect the motor score (Table 1).
None of them received L-DOPA or dopaminergic agonizts. The animals were
observed by different researchers after each dose and as the Parkinsonian
syndrome progressed. Motor symptoms were assessed using a previously
described scale ranging from 0 to 25.35 The degree of disability normally
increased with every new injection and remained stable for years. Animals showing
evident Parkinsonian symptoms after MPTP injection as well as clear impairment of
their motor score were classified as Parkinsonian. Animals with no apparent
Parkinsonian symptoms after MPTP administration were considered asymptomatic.
Non-MPTP-treated animals were grouped as controls (Figure 1 and Table 1). This
classification provided a population of subjects similar to the scenario that occurs in
humans, where symptomatic patients show more than 80% dopaminergic loss,
while some individuals remain asymptomatic despite a starting neurodegenerative
process. We were not able to group the animals into smaller subgroups (e.g. degree
of Parkinsonism or time of survival after MPTP administration) because the sample
would have been too small to ascertain statistically significant differences. Animals
were killed from 1 to 5 years after the last MPTP administration (Table 1).
MPTP mice. Ten-week-old male knockout mice B6.129S7-Ifngtm1Ts/J, TNF-a
knockout mice B6.129S-Tnf. tm1Gkl/J and corresponding parental WT inbred C57BL/
6J mice were purchased from JaxMice (The Jackson Laboratory, Bar Harbor, ME,
USA). The mice were housed in a special room with adequate temperature (211C)
and 12 h day–night cycles. Mice were injected (by intraperitoneal injection) either
with a single dose of MPTP (20 mg/kg) or the same volume of saline and killed 24 h
after the single injection (n¼ 6 per group). All studies were carried out in
accordance with the Guidelines of the European Convention for the protection of
vertebrate animals used for experimental and other scientific purposes of the
Council of Europe of 2006, the Helsinki Declaration and the IACUC of the University
of Murcia.
ELISA determination of IFN-c and TNF-a
Monkey serum extraction. IFN-g and TNF-a concentrations in monkey blood
serum were determined by ELISA detection kit (human IFN-g and human TNF-a,
e-biosciences, San Diego, CA, USA). To withdraw the blood samples, 2 days before
killing, the monkeys were restrained in their own cage by a movable back wall and
the extraction was made through the saphenous vein using a sterile 5 ml syringe
and intravenous needle at between 09:00 and 10:00 hours. No sedative was used to
take the samples. The serum samples were obtained by centrifugation of the
individual blood samples at 3600 r.p.m. for 10 min at room temperature. The
resultant supernatant was aliquoted and stored at 801C until analysis.
Mouse serum extraction. IFN-g and TNF-a concentrations in mouse blood
serum were determined by ELISA detection kit (mouse IFN-g and mouse TNF-a,
e-biosciences). To withdraw the blood samples, mice were anesthetized 24 h after MPTP
injection with ketamine/xylazine for perfusion fixation. Before the perfusion, blood was
obtained by intra-cardial extraction. The serum samples were obtained by centrifugation
of the individual blood samples at 3600 r.p.m. for 10 min at room temperature. The
resultant supernatant was doubly concentrated using a centrifugal filter device (Microcon
YM-10, Millipore, Bedford, MA, USA) and pools of three mice were made to reach
perceptive values. Serum samples were stored at 801C until analysis.
ELISA protocol. Samples from both mice and monkeys were processed with the
following ELISA protocol. The 96-well microplates were coated with the capture
antibody overnight at 41C. The plates were then washed three times with a washing
buffer (PBSþ 0.05% Tween 20), and 100ml of a blocking buffer were added to
each well before incubating for 1 h at room temperature. Subsequently, the plates
were incubated with standards and appropriate dilution of the samples for 1 h at
room temperature (hemolyzed serum samples were discarded). After five washes,
the secondary antibody was added to the wells, and the plates were again incubated
for 1 h at room temperature. The plates were then washed seven more times and
incubated with revealing solution for 15 min. The reaction was stopped by adding
50ml of 2N H2SO4. The absorbance of each well was measured at 450 nm, using a
microplate reader.
Tissue and specific staining
Monkeys. The monkeys were killed with a lethal pentobarbital injection after
ketamine anesthesia 1, 2 or 5 years after the last MPTP dose (Table 1). The brains
were then removed and one brain hemisphere was rapidly frozen with dry ice and
stored at801C for western blot analysis. The other half was fixed for 3 days in 4%
paraformaldehyde dissolved in 0.1 M phosphate buffer. The fixed mesencephalon
was sectioned into 40mm thick serial sections (Microm, HM400). Series of sections
regularly spaced at intervals of 1440mm were stained for tyrosine hydroxylase (TH)
(sheep polyclonal antibody 1 : 500; Chemicon, Temecula, CA, USA) to quantify the
loss of dopaminergic neurons in the MPTP-intoxicated monkeys; for GFAP (rabbit
polyclonal antibody 1 : 500; Chemicon) to analyze the putative astrogliosis in the
SNpc of the Parkinsonian monkeys; for Iba-1 (rabbit polyclonal antibody 1 : 500;
Wako, Chuo-Ku, Osaka, Japan) to determine the population and phenotype of
microglial cells; for human leukocyte antigen-DR (HLA-DR) a-chain CR3/43 clone;
(mouse monoclonal antibody 1 : 50; Dako, Carpinteria, CA, USA) to observe the
microglial activation. Antibodies were also used to detect the expression of
cytokines in the SNpc: anti-human IFN-g (mouse monoclonal, 1 : 100, R&D,
Minneapolis, MN, USA) and anti-human TNF-a (mouse monoclonal, 1 : 100, R&D).
We also used specific antibodies to detect IFN-g receptor (IFN-gR) (mouse
monoclonal antibody 1 : 100; Fitzgerald Industries International, Acton, MA, USA)
and phosphorylated STAT1 (pSTAT1) (mouse monoclonal antibody 1 : 100;
Invitrogen, Carlsbad, CA, USA). Sections from all the animals were stained
simultaneously and under the same experimental conditions.
Mice. One day after MPTP injection, mice were anesthetized intraperitoneally with
an overdose of ketamine (50 mg/kg) and xylazine (50 mg/kg) and perfused-fixed
with oxygenated Tyrode’s solution followed by 4% paraformaldehyde in PBS. Brain
tissue was removed and post-fixed for 48 h before sectioning and further analysis.
All animal experiments were performed after previous approval and conformed to
the policies and procedures of the University of Murcia.
The mesencephalon and the striatum were sectioned into 40 mm thick serial
sections (Vibratome, Leica Microsystem, Wetzlar, Germany). Series of regularly
spaced sections were stained for tyrosine hydroxylase (TH) (sheep polyclonal
antibody 1 : 500; Chemicon); for GFAP to observe astroglial activation (rabbit
monoclonal antibody 1 : 500; Chemicon); for F4/80 (rat antibody 1 : 50; Serotec,
Kidlington, UK) to detect microglial activation and for Iba-1 (rabbit polyclonal
antibody 1 : 500; Wako) to study the microglial phenotype.
Immunohistochemistry and immunofluorescence
DAB detection. For immunohistochemistry, sections of the SNpc (40 mm) were
used to detect specific cells. Endogenous peroxidase activity was inhibited with
0.3% H202 and non-specific Fc binding sites were blocked with 10% horse serum.
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Sections were incubated for 48 h (room temperature, constant shaking) with primary
antibody (see above) diluted in PBS containing 1% horse serum, 0.5% Triton X-100
and 0.1% sodium azide. Sections were incubated for 4 h in secondary antibody
diluted in antibody solution. Antibody binding was detected with the avidin-biotin
peroxidase ABC kit (Vectastain, Vector Labs, Burlingame, CA, USA). Sections were
mounted on gelatin-coated slides and dehydrated in a graded ethanol series and
xylene before being coverslipped.
Immunofluorescence. For immunofluorescence, 40 mm sections were treated
with 0.5% citrate buffer (651C, with constant shaking) for 30 min to maximize
antibody penetration into the tissue. Non-specific Fc binding sites were blocked with
10% horse serum, and sections were incubated for 48 h (room temperature,
constant shaking) with primary antibody diluted in PBS containing 1% horse serum,
0.5% Triton X-100 and 0.1% sodium azide. Sections were incubated for 4 h in
labeled secondary antibody and, after PBS washes, sections were incubated with
DAPI solution (Molecular Probes, Carlsbad, CA, USA) (1 : 1000) in 1 PBS for
30 min. Sections were then washed, mounted and examined to quantify the
fluorescently labeled cells by conventional microscopy (Zeiss Axioplan 2, Standort
Go¨tingen, Germany), or using confocal microscopy (Leica DMIRE2, Wetzlar,
Germany). Appropriate secondary antibodies were used: Alexa 488-conjugated and
Alexa 594-conjugated (1 : 1000) (Molecular Probes).
Histological quantification. SNpc was defined according to the Monkey and
Mouse Brain Atlas.36,37 DAB or fluorescently labeled cells were quantified in serial
coronal sections from each animal. The number of cells was estimated by optical
fractionator probe using a computer assisted image analysis system with a Zeiss
Axioplan 2 microscope connected to a digital camera. The region of interest was
traced using the  1.25 objective. The number of cells was measured in
200 200mm dissectors covering the surface of the analyzed region. Labeled cells
were counted using the  40 objective and counting frames over the delineated
area of the SNpc in each section (optical fractionator). Two representative sections
of the SNpc were used for each stain in monkey brains. These representative
sections were chosen according to the criteria previously defined by Olzewsky and
Baxter.38 The sections contained the ventrolateral area of the SNpc (in primates
corresponding to the aþ b area at the level of the III cranial nerve output), which is
known to show the highest degree of dopaminergic loss and glial activation in
humans39 and non-human primates.35 Four sections of the SNpc were used for
each stain in mouse brain. The data are expressed as the density of cells per mm3 in
each anatomical region analyzed. Results are expressed as the mean±S.E.M.
Confocal analysis. Brain sections were examined using a Leica DMIRE2
confocal microscope with the  63 oil objective and Leica Confocal Software (Leica
Microsystems, Wetzlar, Germany). A series range for each section was set by
determining an upper and lower threshold using the Z/Y position for spatial image
series (for further details see previous publications40). Images can be illustrated as
they appear throughout the stack of sections as a simple 0.5mm layer or as a
transparency of all layers merged together.
Quantification of activated glial phenotype. The activated glial state was
characterized by the expression of specific reactive proteins as described below
(HLA-DR or F4/80 for human or mice microglia, respectively, and GFAP for
astroglia), but also according to the change of phenotype (See Supplementary
Figure 6). To study the glial phenotype, serial sections along the SNpc from
monkeys or mice were stained by immunofluorescence to observe microglial (Iba-1)
or astroglial (GFAP) cells. Sections were scanned with confocal microscope as
described above and primary and secondary branches were quantified along the
z axes in more than 10 cells per animal (more than 50 cells per group). Primary
branches were considered as the first ramification emerging from the cell body and
secondary branches as the ramification emerging from the primary branches. The
microglial or astroglial area was quantified using confocal images of Iba-1 or GFAP.
Scanned confocal planes of 0.5mm containing Iba-1 or GFAP-labeled cells were
processed with Image-J image software (National Institute of Health, Bethesda, MD,
USA) to obtain a black and white image. The area occupied by 50 microglial cells of
the SNpc of each animal was measured in these processed images. The area
occupied by astroglial cells was not measured in monkeys because their processes
were completely intermingled and the software was unable to distinguish and define
each individual cell unit. All quantifications were made blindly by two different
researchers (CMR and MEM).
Western immunoblot
Primary antibodies. To test the specificity of the antibodies used to detect IFN-g
and TNF-a in the SNpc of monkeys, a western immunoblot was performed with anti
TNF-a, diluted 1 : 200 (R&D systems) and Mouse anti IFN-g, diluted 1 : 200 (R&D
systems). GAPDH antibody was used to determine the housekeeping of each
sample (mouse anti GAPDH, 1 : 500, Chemicon).
Preparation of tissue extracts. The SNpc from the frozen half of the tissue of
the monkeys kept at 801C (see details above) was dissected according to the
appropriate coordinates given by the monkey brain atlas,37 using a punching device
designed in our lab of 0.5 cm internal diameter. Tissues were immediately
homogenized with a disposable pellet pestle (Sigma-Aldrich, St. Louis, MO, USA) in
RIPA buffer, containing 50 mM tris/HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 1%
SDS, 1% Triton X-100, 1x cocktail inhibitor (Sigma-Aldrich), 1 mM PMSF, 0.2 mM
Na3VO4 and 1 mM NaF. After centrifugation (15 000 g for 15 min at 41C), a
specific volume of supernatant was analyzed to determine the total concentration of
the protein in the sample using the Micro BCA kit (Pierce, Rockford, IL, USA). Other
aliquots of the samples were mixed with 4 reducing loading buffer (200 mM Tris/
HCl pH 6.8, 4% SDS, 30% glycerol, 4% b-mercaptoethanol, 4% blue bromophenol),
boiled for 3 min and stored at 201C until use.
Electrophoresis and immunoblotting. For each sample, 80mg of proteins
were separated on 15% SDS-polyacrylamide gels. Molecular mass standard
(ColorBurst, Sigma-Aldrich) containing the precisely sized recombinant proteins of
210, 90, 65, 40, 30, 20, 13, 8 kda, positive controls of human recombinant TNF-a
(80 ng) or human recombinant IFN-g (80 ng) (R&D systems), and the samples of the
SNpc were run in the same gel and transferred onto a nitrocellulose membrane. The
samples were run at constant voltage (200 mV) room temperature (RT) for 1 h.
After electrophoresis, protein samples were transferred onto a nitrocellulose
membrane using a transfer buffer (25 mM Tris/HCl, 192 mM glycine, 0.1% SDS,
20% methanol). Pounceau S staining (Bio-Rad, Hercules, CA, USA) was used to
verify equal protein loading in all the lanes.
Non-specific biding sites were blocked by incubation in 5% dry milk diluted in
TTBS 1X (20 mM tris/HCl pH 7.5, 500 mM NaCl, 0.05% tween-20) for 2 h at RT. The
membranes were incubated overnight at 41C in the primary antibody diluted in 3%
BSA, 0.05% NaN3, in TTBS 1x. After rinsing twice with TTBS 1 and thrice with
2.5% dry milk in TTBS 1X, the membranes were incubated for 1 h at RT in ECL
sheep anti mouse IgG, horseradish peroxidase conjugated secondary antibody
(GE healthcare, Little Chalfont, UK) diluted 1 : 5000 in 2.5% dry milk in TTBS 1 .
Antibody binding sites were revealed using ECL plus the western blotting
detection system (GE healthcare). The intensity of the bands was evaluated by
densitometric analysis using ImageJ 1.41 software. The optical density of each
protein band was normalized against the optical density of the GAPDH band used
as internal standard on the same lane. For each independent experiment, the
differences between the experimental groups were expressed as treated/control.
The graphs represent the average of the ratios calculated from five independent
experiments±S.E.M.
Statistical analysis. Data are expressed as mean±S.E.M. Statistical
analysis was performed using a t-test or one-way ANOVA test following a
posthoc analysis (followed by Dunnet or Tukey multiple comparisons tests). The null
hypothesis was rejected for an a risk equal to 5%.
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